Dec 22 - The Serum Institute of India (SII) waived its legal protection from any AstraZeneca-Oxford COVID-19 shot it supplies to a global programme for refugees, a spokesperson for the GAVI vaccination alliance told Reuters on Wednesday.
The news comes days after Reuters told tens of millions of migrants could be denied COVID-19 vaccines in cooperation with the COVAX programme because of the concerns over who would be liable in the event of harmful side-effects.
In the case of refugees, governments aren't the only ones who suffer from these deadly cases.
With the waiver, SII's version of the AstraZeneca-Oxford vaccine, Covishield, can now be allocated to COVAX's - a second-sort reserve that humanitarian groups distribute, said a GAVI representative.
II, world's biggest vaccine manufacturer, which produces a version of Novavax's COVID-19 shot, declined to comment.
AstraZeneca-Serum are currently the main supplier of COVAX-Vidgen-19 vaccines, but are expected to be launched by Pfizer and BioNTech for the first time since 2022.
GAVI was established in 2000 to promote vaccination around the world. That works jointly with the World Health Organization and provides services for poor people who want to get COVID-19 shots.
Our standards: Our standard: ours.